即时检验与批式ELISA法监测英夫利昔单抗和阿达木单抗药物浓度及抗药抗体的比较
该研究比较了新型即用型即时检验免疫分析法CHORUS Promonitor与参考批式ELISA法Promonitor,用于定量检测抗TNF药物英夫利昔单抗(IFX)和阿达木单抗(ADL)的血清药物浓度及抗药抗体。结果显示两种方法在药物浓度检测上定性总体一致率为100%,抗IFX和抗ADL抗体分别为98.8%和97.3%,定量相关性很强(r=0.93~0.97),CHORUS Promonitor与参考方法结果可比。
要点
- CHORUS Promonitor即时检验与批式ELISA法检测IFX和ADL药物浓度的定性总体一致率为100%。
- 抗IFX和抗ADL抗体的定性总体一致率分别为98.8%和97.3%。
- 定量相关性:IFX r=0.97(n=74),ADL r=0.95(n=54),抗IFX r=0.93(n=72),抗ADL r=0.97(n=61)。
核心结论
- CHORUS Promonitor即时检验是定量检测IFX、ADL、抗IFX和抗ADL的可靠方法,结果与参考批式ELISA技术可比。
研究设计与样本
- 研究收集接受抗TNF药物(英夫利昔单抗或阿达木单抗)治疗患者的血液样本。
- 将标准ELISA参考检测Promonitor与自动化即时检验ELISA法CHORUS Promonitor进行定量和定性比较。
- 定性比较计算总体一致性百分比(OPA),定量比较采用Passing-Bablok回归和Bland-Altman分析。
主要发现
- IFX和ADL药物浓度的定性总体一致率为100%(Cohen系数=1)。
- 抗IFX和抗ADL抗体的OPA分别为98.8%和97.3%。
- 定量相关性:IFX(r=0.97,n=74)、ADL(r=0.95,n=54)、抗IFX(r=0.93,n=72)、抗ADL(r=0.97,n=61)。
- 回归分析显示药物浓度方法间可比性极好。
- Bland-Altman分析显示方法间偏倚差异:IFX为6%,ADL为0%,抗IFX为24%,抗ADL为14%。
临床怎么用
- CHORUS Promonitor即时检验可用于监测IFX和ADL药物浓度及抗药抗体,结果与参考批式ELISA可比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare a new ready-to-use monotest immunoassay, CHORUS Promonitor, for the quantification of serum biological drug levels and anti-drug antibodies of anti-TNF agents, against the reference batch-based ELISA test, Promonitor. METHODS: Blood samples were collected from patients treated with anti-TNF agents, infliximab (IFX) or adalimumab (ADL). IFX and ADL levels, as well as anti-IFX and anti-ADL antibodies were quantified and compared between the standard ELISA reference test, Promonitor, and the automated monotest ELISA assay, CHORUS Promonitor. Data analysis included both qualitative and quantitative comparison between both tests. For the qualitative comparison, overall percent agreement (OPA) was calculated. For the quantitative comparison, Passing-Bablok regression analysis and Bland-Altman analysis were used. RESULTS: For IFX and ADL levels, the qualitative overall agreement between methods was 100 % (Cohen's coefficient=1). For anti-IFX and anti-ADL antibodies, OPA was 98.8 % and 97.3 %, respectively. Quantitative comparison indicated a very strong correlation between both assays: IFX (r=0.97, n=74), ADL (r=0.95, n=54), anti-IFX (r=0.93, n=72), and anti-ADL (r=0.97, n=61). The regression analysis determined an excellent comparability of drug levels between methods. Bland-Altman analysis showed a bias difference between assays of 6 % for IFX, 0 % for ADL, 24 % for anti-IFX, and 14 % for anti-ADL. CONCLUSIONS: Monotest CHORUS Promonitor was a reliable assay to quantify IFX, ADL, anti-IFX and anti-ADL in samples with comparable results to those obtained with the reference batch-based ELISA technique.
引用
- Moneo M, Ruiz Del Agua A, Ruiz-Argüello B, et al. Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies. Clin Chem Lab Med. 2025. PMID: 39781652. doi:10.1515/cclm-2024-1258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。